Preventive Health Plan — Personalised Age- and Sex-Stratified Prevention Framework — Cost, Top Hospitals & Success Rates | MyMedicPlus

A preventive health plan (PHP) is a structured, individualised programme of health monitoring, screening, lifestyle intervention, and risk-reduction strategies tailored to a person's age, biological sex, family history, genetic risk profile, occupational exposures, and lifestyle factors. Unlike reactive healthcare — which responds to symptoms — a preventive health plan takes a proactive, forward-looking approach, aiming to detect risk factors and early disease before they cause irreversible harm.

The conceptual framework for preventive health planning is built on three pillars:

• Risk stratification — Accurate assessment of an individual's absolute risk for major conditions (cardiovascular disease, cancer, diabetes, mental health disorders) using validated clinical tools (QRISK3, PHQ-9, GAD-7, Gail Model, Manchester Scoring System for BRCA).
• Evidence-based interventions — Selection of screening tests, vaccinations, lifestyle modifications, and chemoprevention strategies supported by the highest available evidence levels (USPSTF A/B; NICE Grade A; Cochrane systematic reviews).
• Periodic reassessment — Regular scheduled reviews at guideline-recommended intervals, adapting the plan as the patient ages, risk factors change, and new evidence emerges.

The NHS Health Check (offered every 5 years to adults aged 40–74 in England) provides a publicly funded framework for periodic health assessment. However, a comprehensive personalised health plan extends well beyond the NHS Health Check to include mental health, genetic risk, occupational health, travel health, dental and ophthalmic care, and holistic lifestyle medicine. Private preventive health programmes — available through occupational health schemes, private GP practices, and employer-funded health assessments — typically offer a more comprehensive evaluation within a single clinical encounter.

Cost-effectiveness analyses by NICE consistently support well-designed preventive health plans. Interventions that prevent one disability-adjusted life year (DALY) or provide one additional quality-adjusted life year (QALY) at a cost below £20,000–£30,000 are considered cost-effective by NHS standards. Preventive care for smoking cessation, statin therapy, and cancer screening all fall well below this threshold in most modelling scenarios.

A well-designed preventive health plan addresses the leading causes of preventable mortality and morbidity across the life course:

Cardiovascular Disease

CVD accounts for approximately 25% of all UK deaths and is the most preventable major cause of premature mortality. The preventive health plan includes QRISK3 cardiovascular risk calculation, lipid panel assessment, blood pressure monitoring, diabetes screening, smoking cessation support, and evidence-based lifestyle counselling (Mediterranean diet, aerobic exercise). Statin therapy is commenced for QRISK3 ≥10%.

Cancer

Age- and sex-appropriate cancer screening is integrated into the plan: breast (mammography), cervical (HPV primary testing), colorectal (FIT or colonoscopy), lung (low-dose CT in high-risk smokers), and shared-decision PSA testing in eligible men. For individuals with a significant family history, earlier or more intensive screening and genetic referral is incorporated.

Type 2 Diabetes and Metabolic Syndrome

Fasting glucose (or HbA1c) with waist circumference and BMI identifies individuals with metabolic syndrome or non-diabetic hyperglycaemia (pre-diabetes), enabling referral to NHS Diabetes Prevention Programme (NDPP) or equivalent structured lifestyle intervention.

Mental Health

Anxiety and depression are among the leading causes of disability-adjusted life years lost globally. Systematic screening with PHQ-9 (depression) and GAD-7 (generalised anxiety disorder) at periodic health examinations facilitates early identification and stepped-care intervention.

Osteoporosis

FRAX risk tool is used to calculate 10-year major osteoporotic fracture probability in women aged 50+ and men aged 50+ with risk factors. DEXA scanning is indicated for moderate or high FRAX risk. Calcium and vitamin D supplementation, and bisphosphonate therapy if indicated, reduce fracture risk.

Chronic Kidney Disease (CKD)

QRISK3 incorporates CKD as a CVD risk modifier. Annual eGFR and urine ACR monitoring is recommended for individuals with diabetes, hypertension, or cardiovascular disease — the main at-risk groups.

A personalised preventive health plan is appropriate for virtually every adult, but the intensity, content, and frequency of the plan varies by individual risk profile:

• Low-risk adults aged 18–39 — A basic preventive health plan includes: blood pressure check every 3–5 years; BMI and lifestyle assessment; mental health screening (PHQ-9/GAD-7); dental and ophthalmic review; sexual health screening (as appropriate); immunisation review; and reproductive health planning. Cancer screening at this age is limited to cervical screening for eligible persons.
• Moderate-risk adults aged 40–64 — The NHS Health Check framework applies. QRISK3 CVD risk calculation, fasting lipids, glucose, renal function (eGFR/ACR), blood pressure, BMI, waist circumference, smoking status, and alcohol use (AUDIT-C). Cancer screening eligibility begins (bowel, breast, cervical continuation). DEXA for bone health in early postmenopausal women or those with steroid exposure.
• Older adults aged 65+ — More intensive cardiovascular monitoring; fall risk assessment; cognition screening (MMSE, MoCA); hearing and vision testing; polypharmacy review (Beers Criteria/STOPP-START); immunisation update (shingles — Shingrix 2-dose; pneumococcal — PPV23; annual influenza); AAA screening (men at 65, if not previously screened); medication review to reduce anticholinergic burden.
• High-risk individuals with family history — Individuals with first-degree relatives with early-onset CVD (<55 men, <65 women), BRCA-related cancers, Lynch syndrome-associated cancers, or familial hypercholesterolaemia require a more intensive, earlier-onset, and genetically informed preventive plan. Referral to clinical genetics services is appropriate for eligibility assessment for BRCA1/2 testing (Manchester Scoring ≥10%) or Lynch syndrome testing (Amsterdam II criteria or revised Bethesda guidelines).

A comprehensive personalised preventive health plan incorporates the following evidence-based components:

1. Biometric Monitoring

• Blood pressure: Target <140/90 mmHg (general population); <130/80 mmHg (people with diabetes, CKD, or cardiovascular disease). Ambulatory blood pressure monitoring (ABPM) is preferred for diagnosis of hypertension (NICE CG127). Home blood pressure monitoring (HBPM) supports ongoing management.
• BMI and waist circumference: BMI 18.5–24.9 kg/m² is the healthy range. Waist circumference thresholds for increased cardiometabolic risk: >94 cm (men), >80 cm (women); action level: >102 cm (men), >88 cm (women). South Asian ethnic groups have lower BMI and waist thresholds for equivalent risk.
• Fasting glucose and HbA1c: Non-diabetic hyperglycaemia (NDH): fasting glucose 5.5–6.9 mmol/L or HbA1c 39–47 mmol/mol. Triggers NDPP referral. T2DM: HbA1c ≥48 mmol/mol on two occasions.
• Fasting lipid panel: Total cholesterol, LDL-C, HDL-C, non-HDL-C, triglycerides. Non-HDL-C ≥3.4 mmol/L with QRISK3 ≥10% indicates statin initiation. Annual monitoring in high-risk individuals on statin therapy.

2. Mental Health Screening

PHQ-9 (Patient Health Questionnaire-9) scores 0–27: mild (5–9), moderate (10–14), moderately severe (15–19), severe (20–27). A score ≥10 indicates clinically significant depression requiring clinical assessment and stepped-care management. GAD-7 (Generalised Anxiety Disorder-7) score ≥10 indicates moderate-severe anxiety requiring further evaluation. Both tools have strong psychometric properties and are recommended by NICE for systematic screening in primary care settings.

3. Genetic Screening

• BRCA1/2: Mainstreaming cancer genetics (MCG) programmes now offer BRCA testing to eligible individuals based on family history scoring (Manchester Scoring System ≥10%). BRCA1/2 pathogenic variant carriers have a 50–85% lifetime breast cancer risk and 20–50% ovarian cancer risk. Risk-reducing surgery (bilateral salpingo-oophorectomy, risk-reducing mastectomy) and enhanced surveillance MRI are evidence-based options.
• Lynch syndrome: An autosomal dominant DNA mismatch repair (MMR) deficiency syndrome causing hereditary colorectal, endometrial, ovarian, and urological cancers. Amsterdam II criteria and revised Bethesda guidelines identify families warranting mismatch repair immunohistochemistry testing on colorectal cancer specimens. Carriers are offered 2-yearly colonoscopic surveillance from age 25–35.
• Familial hypercholesterolaemia (FH): Autosomal dominant disorder causing severely elevated LDL cholesterol (LDL >5 mmol/L). Simon Broome or Dutch Lipid Clinic criteria used for diagnosis. Cascade genetic testing of first-degree relatives following index case identification is recommended by NICE CG71.

4. Occupational and Travel Health

Occupational health components include workplace hazard assessment, hearing surveillance (audiometry) for noise-exposed workers, hand-arm vibration syndrome (HAVS) monitoring, respiratory surveillance for dust/asbestos/silica exposure, and workplace stress screening. Travel health components include pre-travel consultation for destination-specific vaccines (yellow fever, typhoid, hepatitis A, meningococcal ACWY, Japanese encephalitis) and malaria chemoprophylaxis.

Evidence for the benefits of structured preventive health planning is drawn from population studies, health economic modelling, and clinical trials of individual preventive interventions:

• Cardiovascular event reduction — QRISK3-guided statin initiation produces a 22% relative risk reduction per 1 mmol/L LDL reduction (CTT Collaboration, Lancet 2010). In absolute terms, statin therapy for primary prevention in individuals with ≥10% QRISK3 prevents approximately 5 major vascular events per 100 patients treated over 5 years.
• Cancer mortality reduction — NHS bowel cancer screening reduces colorectal cancer-specific mortality by 25% (Scholefield et al., Gut 2012). Cervical screening has contributed to a 70% reduction in cervical cancer mortality in the UK. Lung cancer CT screening (NLST) reduced lung cancer mortality by 20% in high-risk smokers.
• Mental health outcomes — Early identification of depression using PHQ-9 and delivery of stepped-care treatment (guided self-help, CBT, antidepressants as appropriate) significantly reduces duration of depressive episodes. NICE CG90 stepped care for depression is associated with improved recovery rates at 3 and 12 months.
• Type 2 diabetes prevention — The NHS Diabetes Prevention Programme (NDPP) achieves a 26% reduction in progression from NDH to T2DM (NHS Digital 2022 evaluation). The US Diabetes Prevention Program (DPP) demonstrated a 58% risk reduction with intensive lifestyle intervention versus placebo over a mean 2.8 years follow-up.
• Quality of life and longevity — A comprehensive 2020 analysis in JAMA Network Open estimated that adults who adhere to five healthy lifestyle factors (healthy diet, regular exercise, healthy BMI, non-smoking, low alcohol) at age 50 have a life expectancy 12–14 years greater than those with no healthy lifestyle factors.

A thoughtfully designed preventive health plan minimises harms, but no preventive strategy is entirely without risk:

Overmedicalisation and Health Anxiety

Intensive health monitoring and frequent testing can generate health anxiety in individuals who are fundamentally well. The medicalisation of normal physiological variation (borderline blood pressure, mildly elevated cholesterol, incidental radiological findings) may lead to unnecessary treatment and adverse psychological effects. Clinicians must balance thoroughness with the risk of inadvertently pathologising health and creating “worried well” patients.

Genetic Testing — Psychological and Ethical Considerations

Disclosure of BRCA1/2 pathogenic variants or Lynch syndrome diagnoses has significant psychological consequences for patients and their families. Pre-test and post-test genetic counselling is mandatory to ensure informed consent, manage psychological distress, and navigate decisions about prophylactic surgery and reproductive planning (preimplantation genetic testing).

False-Positive Cascades

Unexpected findings from biometric monitoring or screening tests (an incidental pulmonary nodule on lung CT; a borderline HbA1c; a mildly elevated PSA) trigger diagnostic cascades that consume healthcare resources, generate procedural risk, and cause anxiety — often resolving without any actionable diagnosis.

Health Equity and Access

NHS screening programmes have significant uptake disparities across socioeconomic, ethnic, and geographic groups. Disadvantaged populations — who often have the highest disease burden and stand to gain the most from preventive care — have the lowest participation rates. Deprivation, language barriers, health literacy, and transport access are key structural determinants of preventive care inequity that must be addressed systemically.

Statin and Aspirin Risks

Statins carry a small risk of statin-induced myopathy (1–5/10,000 patient-years for rhabdomyolysis) and new-onset T2DM (approximately 1 extra case per 250 treated for 5 years). Aspirin carries a haemorrhagic risk that outweighs primary prevention benefits in low-risk individuals. Risk-benefit communication must be individualised.

A preventive health plan is a dynamic, living document that must be formally reviewed and updated at regular intervals as the patient ages, risk factors evolve, and evidence bases change:

Annual Reviews

• Blood pressure measurement and cardiovascular risk factor reassessment
• Smoking status and cessation support update
• PHQ-9 / GAD-7 mental health screening (in at-risk individuals or those with prior positive screens)
• Chronic disease management (diabetes, CKD, cardiovascular disease) — annual HbA1c, eGFR, ACR, lipid panel, medication review
• Influenza vaccination (seasonal; all adults ≥65 and clinical risk groups)

3-Yearly Reviews

• Cervical screening (cytology-based, ages 25–29; moving to 5-yearly with HPV primary test from age 30 in UK)
• QRISK3 cardiovascular risk recalculation and decision review for statin therapy
• Mammographic breast screening (50–70, NHS 3-yearly cycle; extending to 47–73)

5-Yearly Reviews

• NHS Health Check (ages 40–74): full CVD risk assessment, diabetes risk, kidney function, dementia risk
• Cervical HPV primary screening (ages 30–64 — 5-yearly)
• Bowel cancer FIT screening (ages 50–74 — 2-yearly in NHS BCS programme)
• FRAX osteoporotic fracture risk reassessment (women post-menopause or at risk)

One-Off Milestones

• AAA ultrasound screening: all men at age 65 (NHS programme)
• Shingrix zoster vaccine: 2-dose series at age 50+
• Pneumococcal PPV23: age 65 (one dose)
• DEXA bone density scan: as indicated by FRAX risk and clinical factors

The preventive health plan should be maintained as a structured, electronic record — ideally integrated into GP clinical systems (EMIS Health, SystmOne) — with automated call-recall for due screening tests and a patient-accessible summary via NHS App or equivalent digital health record.

The economic case for personalised preventive health plans is robust at a population level, though individual plan costs vary widely based on the setting (NHS vs private), intensity of monitoring, and inclusion of genetic testing:

• NHS Health Check: The full NHS Health Check costs approximately £50–£100 per person per 5-year cycle. NHS England modelling estimates that achieving 75% programme uptake would prevent approximately 4,500 heart attacks and strokes, 650 cases of type 2 diabetes, and 2,000 cases of vascular dementia annually in England — representing a highly cost-effective investment.
• Statin therapy: Generic atorvastatin 20 mg costs approximately £0.06–0.15 per tablet (NHS purchasing price). The cost per QALY of statin therapy for individuals with QRISK3 ≥10% is estimated at £2,000–£7,000 — well below the NICE £20,000 threshold. NICE CG181 mandates discussion of statin initiation for all adults with QRISK3 ≥10%.
• Cancer screening: Bowel cancer FIT screening costs approximately £3,000–£5,000 per QALY (HTA modelling); cervical HPV screening £15,000–£20,000 per QALY; lung cancer CT screening £14,000–£25,000 per QALY (NICE 2023). All are within NICE's cost-effectiveness threshold.
• BRCA genetic testing: NHS mainstreaming cancer genetics (MCG) pathways have reduced per-test costs to approximately £200–£500 for BRCA1/2 panel testing. Given the lifetime cancer risk reduction achievable through risk-reducing surgery and surveillance in carriers, the cost per QALY of BRCA testing in eligible populations is consistently below £30,000.
• Private preventive health assessments: Comprehensive private health assessments (e.g., Nuffield Health, BMI Healthcare, BUPA) range from £500 to £2,500 depending on the biomarker panel and imaging included. Full-body MRI screening programmes (available from several private providers) cost £1,500–£3,000 but lack high-quality evidence of mortality benefit in low-risk populations and are not recommended by NICE.
• Smoking cessation: NHS Stop Smoking Services remain the most cost-effective preventive investment in the NHS, with a cost per QALY of approximately £438–£2,000 — orders of magnitude below the NICE threshold.

Several models of preventive care exist, ranging from minimal to highly intensive. The optimal approach is individualised:

Opportunistic Prevention

In the UK NHS, opportunistic prevention occurs when a patient attends for an unrelated reason and is offered brief preventive advice (blood pressure check, smoking cessation brief advice, alcohol screening). Evidence supports this “Making Every Contact Count” (MECC) approach as a low-cost complement to planned prevention, though it is insufficient as a sole strategy for high-risk individuals who rarely consult their GP.

Population-Level Public Health Interventions

Policy-level interventions — sugar taxes (UK Soft Drinks Industry Levy), tobacco taxation and standardised packaging, food labelling legislation, fluoridation of water supplies — address health at a population level without requiring individual clinical assessment. These interventions are complementary to, not substitutes for, individual preventive health plans.

Digital Health and Self-Monitoring

Consumer wearable technology (Apple Watch, FitBit, continuous glucose monitors for non-diabetics) and NHS App-based health services provide individuals with real-time biometric data. The NHS App's Health Record feature provides access to GP records including medications, allergies, and test results. However, digital self-monitoring lacks the clinical interpretation, diagnostic capability, and therapeutic follow-through of a structured clinician-led preventive health plan.

Employer-Based Occupational Health Programmes

Many large employers offer occupational health programmes that include cardiovascular risk screening, mental health support (Employee Assistance Programmes), musculoskeletal assessments, and stress management. These programmes complement but do not replace NHS-based preventive care, and their quality varies significantly.

Minimum Viable Preventive Care

For resource-constrained individuals without access to comprehensive preventive programmes, evidence-based priorities are: (1) smoking cessation; (2) blood pressure management; (3) completion of age-appropriate cancer screening invitations; (4) participation in available vaccination programmes; (5) 150 minutes of weekly physical activity. These five interventions collectively address the majority of the preventable mortality burden.